Candel Gets FDA Fast-Track Designation for CAN-2409 in Non-Small Cell Lung Cancer
By Colin Kellaher Candel Therapeutics Inc. on Monday said the U.S. Food and Drug Administration granted fast-track designation to CAN-2409, the clinical-stage biopharmaceutical company's lead... | April 17, 2023